Drugs / MEM-288
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05076760 | Apr 2022 → Feb 2027 expected | cutaneous neuroendocrine carcinoma, head and neck cancer, malignant pancreatic neoplasm, melanoma +4 | Memgen, LLC | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MEM-288 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05076760 ↗ |
| Route | Other | “Intratumoral injection of MEM-288” NCT05076760 ↗ |